Biorestorative Therapies (BRTX) Projected to Post Earnings on Wednesday

Biorestorative Therapies (NASDAQ:BRTX) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Biorestorative Therapies to post earnings of ($0.20) per share and revenue of $0.3120 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Biorestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.37). Biorestorative Therapies had a negative return on equity of 430.91% and a negative net margin of 3,956.11%.The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.15 million. On average, analysts expect Biorestorative Therapies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biorestorative Therapies Stock Performance

Shares of BRTX stock opened at $0.25 on Wednesday. Biorestorative Therapies has a 1 year low of $0.19 and a 1 year high of $2.05. The stock has a fifty day moving average of $0.25 and a two-hundred day moving average of $0.83. The firm has a market capitalization of $6.47 million, a PE ratio of -0.16 and a beta of 0.29.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC boosted its position in Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares during the period. DRW Securities LLC acquired a new position in Biorestorative Therapies during the 4th quarter worth $55,000. Finally, Citadel Advisors LLC acquired a new position in Biorestorative Therapies during the 3rd quarter worth $152,000. Institutional investors and hedge funds own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.